Last Updated: November 17 2022

Aniracetam is a fat-soluble molecule in the racetams family, anecdotally touted to be more potent than piracetam and more catered to creativity and holistic thinking as well as reducing anxiety and depression. Human studies are lacking.

Aniracetam is most often used for


Aniracetam is a compound in the group of racetams due to its common pyrrolidone structure. It is one of the more common Racetamic structures. It is fat-soluble and thus needs to be ingested with fatty acids. Additionally, Aniracetam is cholinergic

Aniracetam acts as a positive modulator of some excitatory receptors known as AMPA receptors and decreases the rate of receptor desensitization. This typically manifests as a controlled and prolonged neurological stimulation effect. Since AMPA receptors differ in structure across the brain, different AMPA modulators affect the brain in different ways.

Anecdotally, aniracetam has been know to aid in 'collective and holistic thinking', or putting the pieces of the puzzle together. It also increases blood flow and activity in the area of the brain known for this action, the association cortex.

Aniracetam, as an AMPA modulator, is currently being studied for usage in depression and other CNS disorders such as Alzheimer's disease.

What else is Aniracetam known as?
Note that Aniracetam is also known as:
  • Ro 13-5057
  • CAS 72432-10-1
  • 1(4-methoxybenzoyl)-2-pyrrolidinone
  • 1-p-anisoyl-2-pyrrolidinone
Aniracetam should not be confused with:
Dosage information

Doses between 10 mg/kg bodyweight and 100 mg/kg bodyweight have been used in rats with efficacy in laboratory settings. Limited human evidence finds that oral doses in the 1,000-1,500 mg range (over the course of a day) tend to be effective.

Doses as low as 400 mg have been reported to have some efficacy, and it is common to take the above 1,000-1,500 mg aniracetam in two divided doses of 500-750 mg twice daily with meals.

Aniracetam powder has a highly bitter taste, so capsules may be a better purchase for those who wish to avoid that.

Join our supplement information course

Don't miss out on the latest research

3.^Ogiso T, Iwaki M, Tanino T, Ikeda K, Paku T, Horibe Y, Suzuki HPharmacokinetics of aniracetam and its metabolites in ratsJ Pharm Sci.(1998 May)
6.^Zhang J, Liang J, Tian Y, Zhang Z, Chen YSensitive and selective liquid chromatography-tandem mass spectrometry method for the quantification of aniracetam in human plasmaJ Chromatogr B Analyt Technol Biomed Life Sci.(2007 Oct 15)
9.^Bowie DRedefining the Classification of AMPA-selectiveIonotropic Glutamate ReceptorsJ Physiol.(2011 Nov 21. {Epub ahead of print}di)
10.^Ozawa S, Kamiya H, Tsuzuki KGlutamate receptors in the mammalian central nervous systemProg Neurobiol.(1998 Apr)
12.^Francotte P, de Tullio P, Fraikin P, Counerotte S, Goffin E, Pirotte BIn search of novel AMPA potentiatorsRecent Pat CNS Drug Discov.(2006 Nov)
13.^Tang CM, Shi QY, Katchman A, Lynch GModulation of the time course of fast EPSCs and glutamate channel kinetics by aniracetamScience.(1991 Oct 11)
21.^Zhao X, Kuryatov A, Lindstrom JM, Yeh JZ, Narahashi TNootropic drug modulation of neuronal nicotinic acetylcholine receptors in rat cortical neuronsMol Pharmacol.(2001 Apr)
22.^Petkov VD, Grahovska T, Petkov VV, Konstantinova E, Stancheva SChanges in the brain biogenic monoamines of rats, induced by piracetam and aniracetamActa Physiol Pharmacol Bulg.(1984)
23.^Cumin R, Bandle EF, Gamzu E, Haefely WEEffects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodentsPsychopharmacology (Berl).(1982)
25.^Nakamura K, Tanaka YAntidepressant-like effects of aniracetam in aged rats and its mode of actionPsychopharmacology (Berl).(2001 Nov)
27.^Ito I, Tanabe S, Kohda A, Sugiyama HAllosteric potentiation of quisqualate receptors by a nootropic drug aniracetamJ Physiol.(1990 May)
29.^Ouchi Y, Kakiuchi T, Okada H, Nishiyama S, Tsukada HThe effect of aniracetam on cerebral glucose metabolism in rats after lesioning of the basal forebrain measured by PETJ Neurol Sci.(1999 Mar 15)
31.^Knapp RJ, Goldenberg R, Shuck C, Cecil A, Watkins J, Miller C, Crites G, Malatynska EAntidepressant activity of memory-enhancing drugs in the reduction of submissive behavior modelEur J Pharmacol.(2002 Apr 5)
32.^Lauterborn JC, Lynch G, Vanderklish P, Arai A, Gall CMPositive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neuronsJ Neurosci.(2000 Jan 1)
33.^Lauterborn JC, Truong GS, Baudry M, Bi X, Lynch G, Gall CMChronic elevation of brain-derived neurotrophic factor by ampakinesJ Pharmacol Exp Ther.(2003 Oct)
34.^Simmons DA, Rex CS, Palmer L, Pandyarajan V, Fedulov V, Gall CM, Lynch GUp-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin miceProc Natl Acad Sci U S A.(2009 Mar 24)
37.^Kramár EA, Lin B, Lin CY, Arai AC, Gall CM, Lynch GA novel mechanism for the facilitation of theta-induced long-term potentiation by brain-derived neurotrophic factorJ Neurosci.(2004 Jun 2)
38.^O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ESAMPA receptor potentiators for the treatment of CNS disordersCurr Drug Targets CNS Neurol Disord.(2004 Jun)
39.^Vaglenova J, Pandiella N, Wijayawardhane N, Vaithianathan T, Birru S, Breese C, Suppiramaniam V, Randal CAniracetam reversed learning and memory deficits following prenatal ethanol exposure by modulating functions of synaptic AMPA receptorsNeuropsychopharmacology.(2008 Apr)